HONG KONG • A research team at the University of Hong Kong's Aids Institute says it may have found a "functional cure" for HIV, the virus that causes Aids, in a major breakthrough that could see a new antibody be used for both prevention and treatment.
The research by the team led by Professor Chen Zhiwei comes as China is facing a growing epidemic issue among high-risk groups, including sex workers and men who have sex with men.
There are about 850,000 people in China infected with HIV, according to the United Nations-supported Aids Data Hub.
The HIV virus disables the immune system and makes people far more vulnerable to infections and disease.
Prof Chen's discovery, which has been tested on mice, shows that the new antibody can help control the virus and eliminate infected cells.
The antibody would be able to treat all varieties of HIV - a first, Prof Chen said - as there is no one vaccine to treat the many different types of HIV viruses.
"For our newly discovered bispecific antibody, it works for all of them, so that's the major difference," Prof Chen told Reuters.
Prof Chen said a "functional cure" means the virus level would be so low as to be undetectable in the body, as long as people continued taking injections of the antibody, perhaps on a quarterly basis, or less frequently.
The findings by Prof Chen's team have been published in the Journal of Clinical Investigation, one of the world's leading biomedical journals.
People infected with HIV can keep the virus under control with antiretroviral drugs, which stop the virus from infecting new cells.
However, the drugs must be taken daily and do not eliminate the infected cells from the body. The virus can, therefore, still exist and come back if patients stop taking their medication properly.
The new antibody would have a significantly longer half-life than current treatments, and could, for example, be administered on a quarterly basis, Prof Chen said.
This would make it easier to administer than the daily treatment that most HIV infected patients must undergo.
While the results are promising Mr Andrew Chidgey, chief executive of the group Aids Concern in Hong Kong, said it did not mean the treatment would be readily available very soon.
"Governments are being very slow to implement programmes here. So just because a treatment becomes available, doesn't mean that people will get it, or that it will have an impact."
Prof Chen and his team say they are aiming to bring the antibody into clinical trials, and give a time frame of three to five years.
Meanwhile, in more new good news for HIV/Aids sufferers, British pharmaceutical company GlaxoSmithKline said its two-drug treatment for HIV has met its main goal in late-stage studies.
The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK's majority-owned ViiV Healthcare said on Thursday.
It said its push for two-drug regimens addresses long-term toxicity concerns of people living with HIV by reducing the number of medicines they need to take.
GSK rival Gilead Sciences in February won US Food and Drug Administration approval for Biktarvy, a triple-combination HIV treatment, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.